Early research (Phase 1)Study completedNCT01062152
What this trial is testing
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Who this might be right for
Myelodysplastic Syndrome
Telik 19